Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2003
Industry: Medical Technology (Medical supplies, devices, laboratory equipment, diagnostic products)
BD operates through three worldwide segments: BD Medical (injection systems, diabetes care, surgical blades), BD Diagnostics (microbiology, sample collection, diagnostic systems), and BD Biosciences (life sciences research tools). The company employs 24,783 people globally, with significant operations in the U.S. and international markets including Europe, Asia Pacific, and Latin America.
Key Financial Metrics
Note: Specific revenue, net income, cash flow, and debt figures are incorporated by reference to the 2003 Annual Report (pages 22-37) and are not explicitly detailed in the provided text.
- Research & Development (R&D): $235 million for fiscal 2003 (compared to $220 million in 2002 and $212 million in 2001).
- Valuation and Qualifying Accounts (2003):
- Allowance for doubtful accounts ending balance: $32,839,000.
- Allowance for cash discounts ending balance: $14,321,000.
- Total additions charged to costs/expenses: $35,522,000.
- Market Data: As of June 30, 2003, 254,642,080 shares of common stock were outstanding. The aggregate market value of nonaffiliate shares was approximately $9.87 billion.
- Properties: BD owns and leases approximately 13.7 million square feet of facilities worldwide.
Material Changes and Operational Highlights
- R&D Investment: R&D spending increased by approximately $15 million (6.8%) compared to the prior fiscal year.
- Leadership Changes: William A. Kozy became President of BD Diagnostics in November 2003. Vincent A. Forlenza became President of BD Biosciences in March 2003.
- Product Recalls: The company announced voluntary product recalls in July and August 2003.
- Legal Reserves: The company has established reserves for legal defense costs related to latex glove and needlestick litigation but does not anticipate significant one-time charges similar to those recorded in 1998 and 2000.
Guidance, Risks, and Contingencies
Forward-Looking Statements: Management cautions that actual results may differ from expectations due to economic factors, currency fluctuations, competitive pricing, healthcare consolidation, and regulatory changes.
Key Risks and Contingencies:
- Product Liability Litigation: BD is a defendant in approximately 524 lawsuits regarding natural rubber latex gloves (allergic reactions) and four class action suits regarding needlestick injuries. While most latex cases have been closed without liability, the company is vigorously defending remaining suits. A new class action regarding the BD ProbeTec ET instrument was filed in British Columbia in November 2003.
- Antitrust Litigation: Retractable Technologies, Inc. filed an antitrust lawsuit alleging conspiracy to exclude competitors. A trial date was set for February 3, 2004.
- Environmental Matters: BD is involved in Superfund proceedings and state environmental laws. While reserves are established, future charges could materially affect results if estimates prove insufficient.
- Supply Chain: Reliance on sole-source suppliers for certain raw materials poses a risk if supply is interrupted.
- Regulatory: Operations are subject to FDA and foreign agency regulations; non-compliance or product safety concerns could lead to recalls or declining sales.
Investor Verification Checklist
- Verify the specific revenue, net income, and cash flow figures in the "Ten-Year Summary of Selected Financial Data" (pages 22-23 of the 2003 Annual Report) as these are not in the text.
- Review the "Financial Review" section (pages 24-32 of the 2003 Annual Report) for detailed segment performance and margin analysis.
- Monitor the status of the Retractable Technologies antitrust trial scheduled for February 2004.
- Assess the potential financial impact of the new British Columbia class action regarding the ProbeTec ET instrument.
- Confirm the extent of insurance coverage for pending latex and needlestick litigation liabilities.
- Review the details of the voluntary product recalls announced in July and August 2003 for potential operational or reputational impact.